Allianz Asset Management Gmb H Spring Works Therapeutics, Inc. Transaction History

Allianz Asset Management Gmb H

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$36.5 - $52.5 $292,000 - $420,000	8,000 New	8,000 $393,000
Q3 2022 Nov 08, 2022	SELL	$24.1 - $39.66 $2.18 Million - $3.59 Million	-90,509 Reduced 78.7%	24,500 $699,000
Q2 2022 Aug 12, 2022	BUY	$18.36 - $60.07 $1.73 Million - $5.66 Million	94,158 Added 451.58%	115,009 $2.83 Million
Q1 2022 May 13, 2022	SELL	$48.97 - $65.46 $215,174 - $287,631	-4,394 Reduced 17.41%	20,851 $1.18 Million
Q4 2021 Feb 11, 2022	SELL	$53.3 - $75.84 $487,321 - $693,405	-9,143 Reduced 26.59%	25,245 $1.57 Million
Q3 2021 Nov 10, 2021	SELL	$62.66 - $88.26 $986,080 - $1.39 Million	-15,737 Reduced 31.4%	34,388 $2.18 Million
Q2 2021 Aug 16, 2021	SELL	$67.45 - $85.63 $317,284 - $402,803	-4,704 Reduced 8.58%	50,125 $4.13 Million
Q1 2021 May 13, 2021	BUY	$65.1 - $93.59 $2.98 Million - $4.29 Million	45,789 Added 506.52%	54,829 $4.03 Million
Q4 2020 Feb 16, 2021	BUY	$48.36 - $77.92 $437,174 - $704,396	9,040 New	9,040 $656,000

238

69.8M

144K

257K

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.27B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.